Related Experiment Video

Updated: May 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Perspectives on mTOR inhibitors for castration-refractory prostate cancer

Salvatore L Burgio1, Francesco Fabbri, Ian J Seymour

  • 1IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Via Piero Maroncelli 40, 47014 Meldola (FC), Italy.

Current Cancer Drug Targets
|July 27, 2012
PubMed

Insights

Targeting the PI3K/AKT/mTOR pathway shows promise for treating advanced prostate cancer. This research explores mTOR inhibitors for castration-refractory prostate cancer (CRPC) to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol 3'-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is implicated in prostate cancer progression.
  • Deregulation of this pathway is frequently observed during prostate cancer advancement.
  • This pathway plays a crucial role in the transition to androgen-independent disease.

Purpose of the Study:

  • To explore the therapeutic potential of targeting the PI3K/AKT/mTOR pathway in prostate cancer.
  • To review strategies interfering with the PI3K/AKT/mTOR cascade for castration-refractory prostate cancer (CRPC).
  • To present preliminary data on mTOR inhibitors and their suitability for CRPC treatment.

Main Methods:

  • Review of existing literature on PI3K/AKT/mTOR pathway mechanisms in prostate cancer.
  • Analysis of preliminary data on the activity of mTOR inhibitors.
  • Discussion of criteria for selecting suitable mTOR inhibitors for prostate cancer therapy.

Main Results:

  • The PI3K/AKT/mTOR pathway is a significant contributor to prostate cancer progression and resistance to therapy.
  • Various strategies exist to target components of this pathway.
  • Preliminary data suggests mTOR inhibitors have activity relevant to prostate cancer treatment.

Conclusions:

  • Targeting the PI3K/AKT/mTOR pathway offers a promising therapeutic strategy for CRPC.
  • Further evaluation of mTOR inhibitors is necessary to identify optimal treatments.
  • Novel approaches are needed to improve the prognosis for patients with CRPC.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...